<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563290</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00226</org_study_id>
    <secondary_id>NCI-2009-00226</secondary_id>
    <secondary_id>CDR0000576527</secondary_id>
    <secondary_id>OSU-07070</secondary_id>
    <secondary_id>OSU 07070</secondary_id>
    <secondary_id>7813</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <nct_id>NCT00563290</nct_id>
  </id_info>
  <brief_title>Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well dasatinib works in treating patients with
      unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic
      leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the objective response rate (complete response and partial response) in patients
      with unresectable or metastatic squamous cell carcinoma of the skin or RAI stage 0-I chronic
      lymphocytic leukemia receiving dasatinib.

      SECONDARY OBJECTIVES:

      I. Determine the progression-free survival of patients receiving this drug. II. Evaluate
      tumor for presence of total EphA2 and both total and active Src and FAK by
      immunohistochemistry (IHC) pre-treatment with dasatinib.

      III. Evaluate tumor for presence of cyclooxygenase-2 by IHC pre-treatment with dasatinib.

      OUTLINE: Patients are assigned to 1 of 2 treatment arms.

      ARM I: Patients receive 100 mg dasatinib orally (PO) twice daily (BID) on days 1-28.

      ARM II (PATIENTS ENROLLED AFTER 11/18/08): Patients receive 70 mg dasatinib PO BID on days
      1-28.

      In both arms, courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      Pre-therapy tumor biopsy specimens are collected to detect total and phosphorylated Src and
      FAK, total EphA2, and cyclooxygenase-2 by immunohistochemistry.

      After completion of study treatment, patients are followed up monthly for up to 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (Complete Response and Partial Response)</measure>
    <time_frame>Every 2 courses during treatment, assessed up to 12 weeks after completion of treatment</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time from start of treatment to time of progression, assessed up to 12 weeks</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Total EphA2 and Both Total and Active Src and FAK by Immunohistochemistry (IHC)</measure>
    <time_frame>At baseline</time_frame>
    <description>Performed per standard protocols by the Pathology Department.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-2 Presence by IHC</measure>
    <time_frame>At baseline</time_frame>
    <description>Performed per standard protocols by the Pathology Department. Samples will be obtained pre-therapy. Determination of the COX-2 tumor status on this trial will develop the beginnings of a data base upon which future therapy may be designed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Recurrent Skin Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Skin</condition>
  <condition>Stage 0 Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I (dasatinib 100 mg PO BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 100 mg dasatinib PO BID on days 1-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (dasatinib 70 mg PO BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 70 mg dasatinib PO BID on days 1-28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (dasatinib 100 mg PO BID)</arm_group_label>
    <arm_group_label>Arm II (dasatinib 70 mg PO BID)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (dasatinib 100 mg PO BID)</arm_group_label>
    <arm_group_label>Arm II (dasatinib 70 mg PO BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of 1 of the following

               -  Histologically or cytologically confirmed squamous cell carcinoma of the skin

                    -  Unresectable or metastatic disease

                    -  Squamous cell histology represents ≥ 50% of the biopsy specimen

                    -  May or may not be related to autologous or allogeneic organ transplantation

               -  Chronic lymphocytic leukemia (CLL)

                    -  RAI stage 0-I

                    -  Stable disease

          -  Patients with basalosquamous cell disease (basal cell with squamous differentiation)
             are eligible

          -  Measurable disease, defined as at least 1 unidimensionally measurable lesion ≥ 20 mm
             by conventional techniques or ≥ 10 mm by spiral CT scan

          -  Must be willing to undergo a pre-treatment tumor biopsy

          -  Brain metastases are allowed provided the following are true:

               -  Received definitive therapy consisting of external beam radiation therapy, gamma
                  knife therapy, or surgical resection resulting in clinically stable disease

               -  Lesions are under control for at least 4 weeks after completion of definitive
                  therapy, as measured by repeat MRI or CT scans

               -  No requirement for dexamethasone

          -  ECOG performance status 0-1 OR Karnofsky 60-100%

          -  Life expectancy &gt; 6 months

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelets ≥ 100,000/mm^3

          -  Total bilirubin ≤ 1.5 times upper limit of normal(ULN)

          -  AST/ALT ≤ 2.5 times ULN

          -  Potassium 3.5 - 5.1 mmol/L

          -  Calcium &gt; lower limit of normal

          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min

          -  No known HIV 1 or HIV 2 positivity

          -  No known hepatitis C or hepatitis B positivity

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to dasatinib

          -  No QTc prolongation, defined as a QTc interval of ≥ 480 msecs or other significant ECG
             abnormality

          -  No condition that impairs the ability to swallow and retain dasatinib tablets (e.g.,
             gastrointestinal tract disease resulting in an inability to take oral medication,
             requirement for IV alimentation, prior surgical procedure affecting absorption, or
             active peptic ulcer disease)

          -  No clinically significant cardiovascular disease including the following:

               -  Myocardial infarction within 6 months

               -  Uncontrolled angina within 3 months

               -  Diagnosed or suspected congenital long QT syndrome

               -  Any history of clinically significant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, or Torsades de Pointe)

               -  Any history of second or third degree heart block (may be eligible if the subject
                  currently has a pacemaker)

               -  Heart rate consistently &lt; 50 beats/minute on pre-entry ECG

               -  Uncontrolled hypertension

               -  Ejection fraction &lt; 45% by transthoracic echo

          -  No uncontrolled intercurrent illness including, but not limited to, the following:

               -  Ongoing or active infection requiring intravenous antibiotics

               -  History of significant bleeding disorder, including congenital (von Willebrand's
                  disease) or acquired (anti-factor VIII antibodies) disorders

               -  Psychiatric illness or social situations that would limit compliance with study
                  requirements

          -  No prior malignancy except for adequately treated basal cell cancer, carcinoma in situ
             of the cervix, or other cancer for which the patient has been disease free for 3 years

          -  No gastro-esophageal reflux disease dependent on proton pump inhibitors, H2 blockers,
             or antacids

          -  Recovered from prior therapy

          -  No more than 1 prior therapy with a monoclonal antibody

          -  No more than 1 prior chemotherapy regimen

          -  No prior tyrosine kinase inhibitor therapy

               -  Prior erlotinib hydrochloride allowed

          -  More than 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
             and recovered

          -  At least 4 weeks since prior radiotherapy

               -  Measurable disease must be outside the radiotherapy port

          -  At least 2 weeks since prior topical therapy

          -  At least 4 weeks since prior surgery requiring general anesthesia and intubation

          -  At least 120 days (4 months) since prior amiodarone

          -  At least 7 days since prior and no concurrent anti-thrombotic and/or platelet agents
             (e.g., warfarin, heparin, low molecular weight heparin, aspirin [full dose and 81 mg
             dose] and/or ibuprofen)

          -  At least 7 days since prior and no concurrent agents with pro-arrhythmic potential

          -  More than 7 days or 5 half lives, whichever is greater, since prior and no concurrent
             agents or substances that induce or inhibit CYP3A4

          -  No concurrent bisphosphonate therapy for the first 8 weeks of dasatinib treatment

          -  No other concurrent investigational agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Olencki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2015</results_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I Dasatinib</title>
          <description>Patients receive 100 mg orally twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Arm II Dasatinib</title>
          <description>Patients receive 70 mg dasatinib PO BID on days 1-28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I Dasatinib</title>
          <description>Patients receive oral dasatinib 100 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Arm II Dastinib</title>
          <description>Patients receive oral dasatinib 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (Complete Response and Partial Response)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Every 2 courses during treatment, assessed up to 12 weeks after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Dasatinib</title>
            <description>Patients receive 100 mg orally twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Dasatinib</title>
            <description>Patients receive 70 mg orally twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (Complete Response and Partial Response)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Time from start of treatment to time of progression, assessed up to 12 weeks</time_frame>
        <population>The second treatment arm of Dasatinib 70 mg orally twice a day was created as a result of an amendment to the protocol therefore the patient PFS data was combined for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I and Arm II</title>
            <description>For Arm I patients receive Dasatinib100 mg orally twice a day.
For Arm II patients receive Dasatinib 70 mg orally twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>The second treatment arm of Dasatinib 70 mg orally twice a day was created as a result of an amendment to the protocol therefore the patient PFS data was combined for each arm.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Total EphA2 and Both Total and Active Src and FAK by Immunohistochemistry (IHC)</title>
        <description>Performed per standard protocols by the Pathology Department.</description>
        <time_frame>At baseline</time_frame>
        <population>Funding was not available to do correlative studies</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Patients receive 100 mg orally twice a day. Due to a dosing update the dose was decreased to 70 mg orally twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Total EphA2 and Both Total and Active Src and FAK by Immunohistochemistry (IHC)</title>
          <description>Performed per standard protocols by the Pathology Department.</description>
          <population>Funding was not available to do correlative studies</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COX-2 Presence by IHC</title>
        <description>Performed per standard protocols by the Pathology Department. Samples will be obtained pre-therapy. Determination of the COX-2 tumor status on this trial will develop the beginnings of a data base upon which future therapy may be designed.</description>
        <time_frame>At baseline</time_frame>
        <population>Funding was not available to do correlative studies</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Patients receive 100 mg orally twice a day. Due to a dosing update the dose was decreased to 70 mg orally twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>COX-2 Presence by IHC</title>
          <description>Performed per standard protocols by the Pathology Department. Samples will be obtained pre-therapy. Determination of the COX-2 tumor status on this trial will develop the beginnings of a data base upon which future therapy may be designed.</description>
          <population>Funding was not available to do correlative studies</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients will be evaluated for Adverse Events from week 1 up until 12 weeks.</time_frame>
      <desc>Toxicities were graded using the Common Toxicity Criteria Version 3.0 (CTC 3.0)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib 100 mg</title>
          <description>Patients receive the initial dose of 100 mg orally twice a day.</description>
        </group>
        <group group_id="E2">
          <title>Dasatinib 70 mg</title>
          <description>Patients receive the initial dose of 70 mg orally twice a day. Dose was reduced to 70 mg orally based on toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>unknown ANC</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>unknown ANC</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vascular- other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>3 patients were treated with Dasatinib 100 mg PO twice daily and 4 patients were treated with Daatinib 70 mg PO twice daily.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Olencki, DO</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-2886</phone>
      <email>Thomas.Olencki@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

